Retina

Recent improvements in electroretinography are making the technique more accessible for general use. It has a wide range of clinical applications.

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Ian C. Han, MD, assistant professor in the Department of Ophthalmology and Visual Sciences, Institute for Vision Research, University of Iowa Hospital and Clinics, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

With NASA’s sights set on Mars, continued research into further understanding and mitigating spaceflight-associated neuro-ocular syndrome is of the utmost importance for astronaut health and space exploration.

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.

Study found that YAG laser vitreolysis was less invasive than pars plana vitrectomy for patients with vitreous opacities.

Community support is the most important factor in ascertaining effective treatments for paediatric eye diseases.

Diabetes mellitus, which is a common chronic disease in children, can lead to significant eye morbidities with long-lasting effects, including diabetic retinopathy. Treatment should be tailored to the individual patient.

Faricimab is the focus of the YOSEMITE and RHINE studies, which investigators say show that the investigational bispecific antibody has the potential to offer lasting vision improvements for patients with diabetic macular oedema.

Prospective randomised trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

Good early adherence to label regimens can make a difference, yielding vision outcomes approaching those in clinical trials, emerging real-world studies of anti-VEGF for DMO suggest.

As OCT-A devices become faster, the algorithms advance and the instrument costs decrease, more widespread utilisation in retina practices is likely.

In this roundtable, members of the Ophthalmology Times Europe® Editorial Advisory Board consider the top challenges and opportunities that they anticipate will affect ophthalmology in Europe in 2021.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

A case series of 13 young patients with Charles Bonnet syndrome, which is characterised by visual hallucinations in individuals who are experiencing sight loss, showed that the patients all had inherited retinal diseases or congenital eye disorders but there was no link with visual dysfunction.

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.

Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.

At AAO 2020, Fernando Arevalo, MD, PhD, details the use of anti-VEGF therapy for the treatment of retinal arteriolar macroaneurysms that are near the fovea.

COVID-19 has had a significant impact on the entire global community. As we look to the future to advance the provision of eyecare excellence, opportunities for innovation must be embraced and new, patient-centric ways of managing clinical practices adopted.

Dr Anna Stulova, fellow, Ophthalmology Department, Faculty of Medicine, Lomonosov Moscow State University, is among those recognised in this year’s program.

Dietary macular pigments, which can now be measured directly and accurately, are hugely important in optimising visual function, especially as we age.

To maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimise clinic visits and maximise use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximising safety and patients’ vision outcomes.

Photobiomodulation has been demonstrated to improve quality of vision in several patients suffering from dry AMD.

Novel monoclonal antibody can halt the growth of abnormal blood vessels

SS-OCT provides a clear view of the eye’s internal structures and any abnormalities, helping to differentiate benign from malignant lesions.

Recent international ophthalmic congresses have featured advocates for and against the need for complete fluid resolution when treating nAMD, with some ophthalmologists arguing for a zero-tolerance approach to the presence of fluid, and others claiming some residual fluid can be tolerated and may be helpful in some patients.

The one-piece, small-aperture IOL IC-8 was found in a retrospective comparative review of studies to enhance vision at all distances, with improved visual acuities and a broad range of continuous functional vision.